Directly observed treatment, short-course strategy and multidrug- resistant tuberculosis: Are any modifications required?

Bulletin of the World Health Organization

Volumn 78, Issue 2, 2000, Pages 238-251

  Bastian, I ^a   Rigouts, L ^a   Van Deun, A ^a   Portaels, F ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Antitubercular agents, administration and dosage, and supply and distribution; Drug therapy, combination; Treatment failure; Tuberculosis, multidrug resistant, drug therapy and epidemiology

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; EVALUATION; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HUMAN; INCIDENCE; MULTIDRUG RESISTANCE; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 0034061529     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Harris HW. Chemotherapy of tuberculosis the beginning. In: Rom WN, Garay SM, eds. Tuberculosis. Boston, Little Brown and Co., 1996. 745-749.
2. Sensi P. History of the development of rifampin. Reviews of Infectious Diseases, 1983, 5 (Suppl 3) S402-S406.
3. Schluger NW, Harkin TJ, Rom WN. Principles of therapy of tuberculosis in the modern era In: Rom WN, Garay SM, eds Tuberculosis. Boston, Little Brown & Co , 1996: 751-761
4. Murray CJ, Salomon JA. Modeling the impact of global tuberculosis strategies. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95: 13 881-13 886
5. Pablos-Méndez A et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. New England Journal of Medicine, 1998, 338. 1641-1649.
6. Antituberculosis Drug Resistance in The World: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1994-1997. Geneva, World Health Organization, 1997 (unpublished document WHO/TB/97.229).
7. WHO Tuberculosis Programme: Framework for effective Tuberculosis Control. Geneva, World Health Organization, 1994 (unpublished document WHO/TB/94.179).
8. Kochi A. Tuberculosis control - is DOTS the health breakthrough of the 1990s? World Health Forum, 1997, 18. 225-247
9. Global Tuberculosis Control, WHO Report 1999. Geneva, World Health Organization, 1999 (unpublished document WHO/CDS/ CPCTB/99 259)
10. De Cock KM, Chaission RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. International Journal of Tuberculosis and Lung Disease, 1999, 3: 457-465.
11. Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". British Medical Journal, 1998, 317: 671-674
12. Farmer P et al. The dilemma of MDRTB in the global era. International Journal of Tuberculosis and Lung Disease, 1998, 2. 869-876
13. Iseman MD. MDR-TB and the developing world - a problem no longer to be ignored the WHO announces 'DOTS Plus' strategy. International Journal of Tuberculosis and Lung Disease, 1998, 2: 867.
14. Espinal M. Multidrug-resistant tuberculosis: basis for the development of an evidence-based case-management strategy for MDR-TB within the WHO's DOTS strategy. Proceedings of 1998 meetings and protocol recommendations Geneva, World Health Organization, 1997 (unpublished document WHO/TB/99 260).
15. Espinal MA et al. Rational 'DOTS plus' for the control of MDR-TB. International Journal of Tuberculosis and Lung Disease, 1999, 3: 561-563.
16. Chaulet P, Boulahbal F, Grosset J. Surveillance of drug resistance for tuberculosis control: why and how? Tubercle and Lung Disease, 1995, 76: 487-492.
17. Cohn DL, Bustreo F, Raviglione MC. Drug-resjstant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clinical Infectious Diseases, 1997, 24 (Suppl 1): S121-S130.
18. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons - Florida and New York, 1988-1991. Morbidity and Mortality Weekly Report, 1990, 40: 585-591.
19. Dooley SW et al. Multidrug-resistant tuberculose. Annals of Internal Medicine, 1992, 117: 257-258.
20. Outbreak of hospital acquired multidrug resistant tuberculosis. Communicable Disease Report Weekly, 1995, 5: 161.
21. Herrera D et al. Multidrug-resistant tuberculosis outbreak on an HIV ward - Madrid, Spain, 1991-1995. Morbidity and Mortality Weekly Report, 1996, 45: 330-333.
22. Moro ML et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. AIDS, 1998, 12: 1095-1102.
23. Jereb JA et al. Tuberculosis in health care workers at a hospital with an outbreak of multidrug-resistant Mycobacterium tuberculosis. Archives of Internal Medicine, 1995, 155: 854-859.
24. Iseman MD. Treatment of multidrug-resistant tuberculosis. New England Journal of Medicine, 1993, 329: 784-791.
25. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. Journal of the American Medical Association, 1993, 270. 65-68
26. Outbreak of multidrug-resistant tuberculosis - Texas, California, and Pennsylvania. Morbidity and Mortality Weekly Report, 1990, 39: 369-372.
27. Bloch AB et al. Nationwide survey of drug-resistant tuberculosis in the United States. Journal of the American Medical Association, 1994, 271: 665-671.
28. Frieden TR et al. Tuberculosis in New York City - turning the tide. New England Journal of Medicine, 1995, 333: 229-233.
29. Moore M et al. Trends in drug-resistant tuberculosis in the United States, 1993-1996. Journal of the American Medical Association, 1997, 278. 833-837.
30. Irish C et al. Database study of antibiotic resistant tuberculosis in the United Kingdom, 1994-6. British Medical Journal, 1999, 318: 497-498.
31. Wanlin M et al. [Tuberculosis: multiresistance in Belgium, 1992 and 1993 ] Acta Clinica Belgica, 1996, 51 150-155 (in French).
32. Fischer B. Epidemiology of mycobacterial resistance (especially Mycobacterium tuberculosis). Chemotherapy, 1999, 45: 109-120.
33. Nutini S et al. Multidrug-resistant tuberculosis in the Florence province from 1992 to 1995. International Journal of Tuberculosis and Lung Disease, 1998, 2: 484-489.
34. Hirano K et al. Resistance to antituberculosis drugs in Japan. Tubercle and Lung Disease, 1996, 77: 130-135
35. Dawson D. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 1994 and 1995. Communicable Diseases Intelligence, 1997, 21: 245-249
36. Telzak EE et al. Multidrug-resistant tuberculosis in patients without HIV infection. New England Journal of Medicine, 1995, 333: 907-911.
37. Riley LW, Arathoon E, Loverde VD. The epidemiologic patterns of drug-resistant Mycobacterium tuberculosis infections: a community-based study American Review of Respiratory Diseases, 1989, 139: 1282-1285.
38. Glynn JR et al. Patterns of initial and acquired antituberculosis drug resistance in Karonga District, Malawi. Lancet, 1995, 345: 907-910.
39. Estimates of future global tuberculosis morbidity and mortality. Morbidity and Mortality Weekly Report, 1993, 42. 961-964.
40. Zhang LX et al. Trend of initial drug resistance of tubercle bacilli isolated from new patients with pulmonary tuberculosis and its correlation with the tuberculosis programme in Beijing. Tubercle and Lung Disease, 1995, 76: 100-103
41. Hadiarto M, Tjandra YA, Hudoyo A. Treatment of multidrug-resistant tuberculosis in Indonesia. Chemotherapy, 1996, 42 (Suppl 3): 24-29
42. Mendoza MT et al. Nature or drug resistance and predictors of multidrug-resistant tuberculosis among patients seen at the Philippine General Hospital, Manila, Philippines. International Journal of Tuberculosis and Lung Disease, 1997, 1: 59-63.
43. Portaels F. Multidrug resistant tuberculosis. In: Book of Abstracts from the Eighth International Congress on Infectious Diseases, Boston 15-18 May 1998, 1998: 108.
44. Healing TD et al. Antibiotic resistance among isolates of Mycobacterium tuberculosis from Tomsk region, Western Siberia. In: Proceedings of The Second European Congress on Tropical Medicine, Liverpool 14-18 September 1998, 1998: 116.
45. Coninx R et al. Drug resistant tuberculosis in prisons in Azerbaijan: case study. British Medical Journal, 1998, 316: 1423-1425.
46. Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. International Journal of Tuberculosis and Lung Disease, 1999, 3: 582-588.
47. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children American Journal of Respiratory and Critical Care Medicine, 1994, 149. 1359-1374.
48. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle, 1985, 66: 219-225.
49. Dutt AK, Moers D, Stead WW. Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. American Journal of Medicine, 1984, 77: 233-242.
50. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. American Review of Respiratory Diseases, 1987, 136: 1339-1342.
51. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive tuberculosis, including an assessment of a combination preparation of isoniazid.rifampin, and pyrazinamide: results at 30 months. American Review of Respiratory Diseases, 1991, 143: 700-706.
52. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21 effectiveness, toxicity, and acceptability. The report of final results. Annals of Internal Medicine, 1990, 112: 397-406.
53. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis American Review of Respiratory Diseases, 1986, 133. 423-430
54. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. American Review of Respiratory Diseases, 1979, 119: 579-585
55. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. American Review of Respiratory Diseases, 1977, 115. 727-735.
56. Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs, 1999, 58: 633-661
57. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin International Journal of Tuberculosis and Lung Disease, 1998, 2: 877-884.
58. Goble M et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. New England Journal of Medicine, 1993, 328: 527-532.
59. Kim SJ, Bai GH, Hong YP. Drug-resistant tuberculosis in Korea, 1994. International Journal of Tuberculosis and Lung Disease, 1997, 1: 302-308.
60. Boulahbahl F, Khaled S, Tazir M. The interest of follow-up of resistance of the tubercle bacillus in the evaluation of a programme. Bulletin of the International Union against Tuberculosis and Lung Disease, 1989, 64: 23-25.
61. Treatment of tuberculosis: guidelines for national programmes, 2nd edition. Geneva, World Health Organization, 1997 (unpublished document WHO/TB/97.220)
62. Coninx R et al. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet, 1999, 353. 969-973.
63. Rigouts L, Portaels F. DNA fingerprints of Mycobacterium tuberculosis do not change during the development of resistance to various antituberculosis drugs. Tubercle and Lung Disease, 1994, 75: 160.
64. Chaves F et al. Evidence of exogenous reinfection and mixed infection with more than one strain of Mycobacterium tuberculosis among Spanish HIV-infected inmates. AIDS, 1999, 13: 615-620.
65. Mühlberger et al. Ofloxacin-cycloserine-prothionamide-INH combination against treatment refractory lung tuberculosis. Pneumologie, 1995, 49: 72-76.
66. Van Deun A, Portaels F. Preliminary results with ofloxacin-containing standard regimens for multidrug resistant TB. International Journal of Tuberculosis and Lung Disease, 1998, 2 (Suppl. 2): S374.
67. Crofton J et al. Guidelines for the management of drug-resistant tuberculosis. Geneva, World Health Organization, 1997 (unpublished document WHO/TB/96.210).
68. Heifets L, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis - a neglected problem at the turn of the century. International Journal of Tuberculosis and Lung Disease, 1999, 3: 564-581.
69. Hong Kong Tuberculosis Treatment Services/British Medical Research Council. A study in Hong Kong to evaluate the role of pretreatment susceptibility tests in the selection of regimens of chemotherapy for pulmonary tuberculosis - second report. Tubercle, 1974, 55: 169-192.
70. Coates ARM, Mitchison DA. The role of sensitivity tests in short-course chemotherapy Bulletin of the International Union against Tuberculosis, 1983, 58: 110-114.
71. Heifets LB. Drug susceptibility tests in the management of chemotherapy of tuberculosis. In: Heifets LB, ed Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. Boca Raton, FL, CRC Press, 1991: 89-121.
72. Drobniewski F et al. Tuberculosis in Siberia: 2. Diagnosis, chemoprophylaxis and treatment. Tubercle and Lung Disease, 1996, 77: 297-301.
73. Pfyffer GE et al. Multicentre laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. Journal of Clinical Microbiology, 1999, 37: 3179-3186
74. Laszlo A et al. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/ IUATLD supranational laboratory network. first round of proficiency testing International Journal of Tuberculosis and Lung Disease, 1997, 1: 231-238.
75. International Drug Price Indicator Guide, 1998. Arlington, VA, Management Sciences for Health and The World Bank, 1998.
76. Sullivan EA et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet, 1995, 345: 1148-1150.
77. Bartlett JG et al. Community-acquired pneumonia in adults: guidelines for management. Clinical Infectious Diseases, 1998, 26: 811-838.
78. Murray CJL, Styblo K, Rouillon K. Tuberculosis in developing countries: burden, intervention and cost. Bulletin of the International Union against Tuberculosis and Lung Disease, 1990, 65: 6-24.
79. Frieden TR. What should be the response to a reported rise in drug-resistant tuberculosis? International Journal of Tuberculosis and Lung Disease, 1998, 2 (Suppl 2): S180-S181.